# EDGAR Filing Document

**Accession Number:** 0001604464
**File Stem:** 0000950170-23-011416
**Filing Date:** 2023-3
**Character Count:** 5099
**Document Hash:** 2b237321ef887ef726ec2d93df86269c
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000950170-23-011416.hdr.sgml**: 20230331

**ACCESSION NUMBER**: 0000950170-23-011416

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20230331

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**FILED AS OF DATE**: 20230331

**DATE AS OF CHANGE**: 20230331

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Atara Biotherapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001604464
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **IRS NUMBER:** 460920988
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36548
- **FILM NUMBER:** 23788340

**BUSINESS ADDRESS:**
- **STREET 1:** 2380 CONEJO SPECTRUM ST
- **STREET 2:** SUITE 200
- **CITY:** THOUSAND OAKS
- **STATE:** CA
- **ZIP:** 91320
- **BUSINESS PHONE:** 805-623-4244

**MAIL ADDRESS:**
- **STREET 1:** 2380 CONEJO SPECTRUM ST
- **STREET 2:** SUITE 200
- **CITY:** THOUSAND OAKS
- **STATE:** CA
- **ZIP:** 91320

?xml version="1.0" encoding="ASCII"? 8-K

------

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

------

**FORM** 8-K

------

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported):** March 31, 2023

------

ATARA BIOTHERAPEUTICS, INC.

**(Exact Name of Registrant as Specified in Its Charter)**

------

---

| | | |
|:---|:---|:---|
| Delaware  | 001-36548 | 46-0920988 |
| **(State or Other Jurisdiction**<br>**of Incorporation or Organization)** | **(Commission**<br>**File No.)** | **(IRS Employer**<br>**Identification No.)** |

---

---

| | |
|:---|:---|
| 2380 Conejo Spectrum Street**,** Suite 200<br>Thousand Oaks**,** CA | 91320 |
| **(Address of Principal Executive Offices)** | **(Zip Code)** |

---

**Registrant's Telephone Number, Including Area Code:** (805) 623-4211

**Not Applicable**

**(Former Name or Former Address, if Changed Since Last Report)**

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading**<br>**Symbol(s)** | **Name of Each Exchange**<br>**on Which Registered** |
| Common Stock, par value $0.0001 per share | ATRA | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**ITEM 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers**

On February 3, 2023, Atara Biotherapeutics, Inc., a Delaware corporation (the "Company"), announced that Utpal Koppikar, the Company's Executive Vice President, Chief Financial Officer, notified the Company of his intention to resign from the Company effective as of March 31, 2023.

On March 31, 2023, Mr. Koppikar resigned from the Company and entered into a consulting agreement with the Company, pursuant to which Mr. Koppikar will provide consulting services to the Company for a six-month term. Mr. Koppikar will be paid a consulting fee of $2,800 monthly for up to a specified number of consulting hours per month and will receive additional compensation of $175 per hour in excess of such specified number of consulting hours. Mr. Koppikar's outstanding equity awards will continue to vest during the consulting term.

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | |
|:---|:---|
| **Atara Biotherapeutics, Inc.** | **Atara Biotherapeutics, Inc.** |
| By: | /s/ Amar Murugan |
|  | Amar Murugan |
|  | Executive Vice President, Chief Legal Officer |

---

Dated: March 31, 2023

------